Adolor gastrointestinal, neurology news
Adolor restructured and reduced headcount by 45 (28%) to about 116 in discovery to focus on its marketed drug Entereg alvimopan and clinical programs. Adolor co-promotes Entereg, a selective peripherally acting mu opioid receptor antagonist, for postoperative ileus (POI) with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) in the U.S. The company will also focus on its delta opioid receptor agonist program for pain, which includes ADL5859 (PF-04856880) has completed a Phase II trial and ADL5747 ( PF-04856881) in Phase I. Pfizer Inc. (NYSE:PFE, New York, N.Y.) has exclusive, worldwide rights to the pain compounds under a 2007 deal. Adolor also has ADL7445, a mu opioid receptor antagonist, with Phase I testing for opioid-induced bowel dysfunction (OBD) planned for later this year. ...